SCHEMBL1937010

SCHEMBL1937010

OC(=S)N1CCSCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21382091 0.75
SCHEMBL1127327 0.74
SCHEMBL5126603 0.74
SCHEMBL28409402 0.74 CA1 (0.44)
SCHEMBL2858061 0.71
SCHEMBL337228 0.71
SCHEMBL2442152 0.69
SCHEMBL187410 0.69 CA1 (0.55)
SCHEMBL10457653 0.69 DPP4 (0.53)
SCHEMBL19880292 0.69 FAAH (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10882861-B2 Purine nucleotide derivatives THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2021-01-05 US claimed
US-20190300532-A1 PURINE NUCLEOTIDE DERIVATIVES THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2019-10-03 US claimed
WO-2017201382-A1 PURINE NUCLEOTIDE DERIVATIVES THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2017-11-23 WO claimed
US-4826852-A Novel ergolinyl compounds nitrogen-substituted in the 8-position, useful for treating dopamine deficiency SCHERING AKTIENGESELLSCHAFT (DE) 1989-05-02 US claimed
EP-0082808-B1 NOVEL ERGOLINYL COMPOUNDS NITROGEN-SUBSTITUTED IN THE 8-POSITION, THEIR PREPARATION, AND USE AS MEDICINAL AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 1987-05-27 EP claimed
EP-0082808-A1 Novel ergolinyl compounds nitrogen-substituted in the 8-position, their preparation, and use as medicinal agents SCHERING AKTIENGESELLSCHAFT (DE) 1983-06-29 EP claimed
EP-4740010-A1 NEGATIVE TUNE STANDARD FOR MASS SPECTROMETRY Agilent Technologies, Inc. (US) 2026-05-13 EP disclosed
US-20260109989-A1 COMPOSITIONS AND METHODS FOR THE SYNTHESIS AND IDENTIFICATION OF COVALENT APTAMERS UNIV HAWAII (US) 2026-04-23 US disclosed
US-12371694-B2 Compositions and methods for the synthesis and identification of covalent aptamers UNIVERSITY OF HAWAII (US) 2025-07-29 US disclosed
WO-2025010077-A1 NEGATIVE TUNE STANDARD FOR MASS SPECTROMETRY AGILENT TECHNOLOGIES, INC. (US) 2025-01-09 WO disclosed
EP-4441066-A1 SYNTHESIS OF 2' ACETYL-ESTER PROTECTED NUCLEOSIDES Hongene Biotech Corporation (US) 2024-10-09 EP disclosed
CN-118317970-A Synthesis of 2' acetyl-ester protected nucleosides 兆维生物科技公司 2024-07-09 CN disclosed
US-11897914-B2 Synthesis of 2′ protected nucleosides HONGENE BIOTECH CORPORATION (US) 2024-02-13 US disclosed
US-20160002282-A1 Protected Monomer and Method of Final Deprotection for RNA Synthesis AGILENT TECHNOLOGIES, INC. 2016-01-07 US disclosed
US-20120289691-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2012-11-15 US disclosed
US-20120184724-A1 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2012-07-19 US disclosed
EP-2331558-A2 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS Agilent Technologies, Inc. (US) 2011-06-15 EP disclosed
US-20100076183-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. 2010-03-25 US disclosed
US-4826852-A Novel ergolinyl compounds nitrogen-substituted in the 8-position, useful for treating dopamine deficiency SCHERING AKTIENGESELLSCHAFT (DE) 1989-05-02 US disclosed
EP-0082808-B1 NOVEL ERGOLINYL COMPOUNDS NITROGEN-SUBSTITUTED IN THE 8-POSITION, THEIR PREPARATION, AND USE AS MEDICINAL AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 1987-05-27 EP disclosed